Advertisement

Molecular and Cellular Biochemistry

, Volume 444, Issue 1–2, pp 143–148 | Cite as

Effects of homocysteine and its related compounds on oxygen consumption of the rat heart tissue homogenate: the role of different gasotransmitters

  • Jovana Jakovljević Uzelac
  • Marina Stanić
  • Danijela Krstić
  • Mirjana Čolović
  • Dragan Djurić
Article

Abstract

The objective of this study was to investigate in vitro effects of 10 µM dl-homocysteine (dl-Hcy), dl-homocysteine thiolactone-hydrochloride (dl-Hcy TLHC), and l-homocysteine thiolactone-hydrochloride (l-Hcy TLHC) on the oxygen consumption of rat heart tissue homogenate, as well as the involvement of the gasotransmitters NO, H2S and CO in the effects of the most toxic homocysteine compound, dl-Hcy TLHC. The possible contribution of the gasotransmitters in these effects was estimated by using the appropriate inhibitors of their synthesis (N ω-nitro-l-arginine methyl ester (l-NAME), dl-propargylglycine (dl-PAG), and zinc protoporphyrin IX (ZnPPR IX), respectively). The oxygen consumption of rat heart tissue homogenate was measured by Clark/type oxygen electrode in the absence and presence of the investigated compounds. All three homocysteine-based compounds caused a similar decrease in the oxygen consumption rate compared to control: 15.19 ± 4.01%, 12.42 ± 1.01%, and 16.43 ± 4.52% for dl-Hcy, dl-Hcy TLHC, or l-Hcy TLHC, respectively. All applied inhibitors of gasotransmitter synthesis also decreased the oxygen consumption rate of tissue homogenate related to control: 13.53 ± 1.35% for l-NAME (30 µM), 5.32 ± 1.23% for dl-PAG (10 µM), and 5.56 ± 1.39% for ZnPPR IX (10 µM). Simultaneous effect of l-NAME (30 µM) or ZnPPR IX (10 µM) with dl-Hcy TLHC (10 µM) caused a larger decrease of oxygen consumption compared to each of the substances individually. However, when dl-PAG (10 µM) was applied together with dl-Hcy TLHC (10 µM), it attenuated the effect of dl-Hcy TLHC from 12.42 ± 1.01 to 9.22 ± 1.58%. In conclusion, cardiotoxicity induced by Hcy-related compounds, which was shown in our previous research, could result from the inhibition of the oxygen consumption, and might be mediated by the certain gasotransmitters.

Keywords

Homocysteine Homocysteine thiolactone Gasotransmitters Oxygen consumption Rat heart tissue homogenate 

Notes

Acknowledgements

The authors would like to thank to the Ministry of Education, Science and Technological Development of the Republic of Serbia (Projects Nos. OI 175043 and OI 173040) for the financial support.

Compliance with ethical standards

Conflict of interest

The authors confirm that this article content has no conflict of interest.

References

  1. 1.
    Heneghan HM, Sultan S (2008) Homocysteine, the cholesterol of the 21st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for critical limb ischemia. J Endovasc Ther 15:399–407CrossRefPubMedGoogle Scholar
  2. 2.
    Kaplan ED (2003) Association between homocyst(e)ine levels and risk of vascular events. Drugs Today 39:175–192CrossRefPubMedGoogle Scholar
  3. 3.
    Homocysteine Studies C (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022CrossRefGoogle Scholar
  4. 4.
    Townsend DM, Tew KD, Tapiero H (2004) Sulfur containing amino acids and human disease. Biomed Pharmacother 58:47–55CrossRefPubMedGoogle Scholar
  5. 5.
    Jakubowski H (1997) Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 272:1935–1942PubMedGoogle Scholar
  6. 6.
    Jakubowski H, Boers GH, Strauss KA (2008) Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J 22:4071–4076CrossRefPubMedGoogle Scholar
  7. 7.
    Jakubowski H (1999) Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 13:2277–2283CrossRefPubMedGoogle Scholar
  8. 8.
    Rasic-Markovic A, Stanojlovic O, Hrncic D, Krstic D, Colovic M, Susic V et al (2009) The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administration. Mol Cell Biochem 327:39–45CrossRefPubMedGoogle Scholar
  9. 9.
    Harker LA, Ross R, Slichter SJ, Scott CR (1976) Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Investig 58:731–741CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Flesch M, Kilter H, Cremers B, Lenz O, Sudkamp M, Kuhn-Regnier F et al (1997) Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 281:1340–1349PubMedGoogle Scholar
  11. 11.
    Paulus WJ (2001) The role of nitric oxide in the failing heart. Heart Fail Rev 6:105–118CrossRefPubMedGoogle Scholar
  12. 12.
    Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M et al (2006) Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol 149:625–634CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Laggner H, Muellner MK, Schreier S, Sturm B, Hermann M, Exner M et al (2007) Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic Res 41:741–747CrossRefPubMedGoogle Scholar
  14. 14.
    Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS et al (2004) The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’? J Neurochem 90:765–768CrossRefPubMedGoogle Scholar
  15. 15.
    Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS et al (2005) Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem Biophys Res Commun 326:794–798CrossRefPubMedGoogle Scholar
  16. 16.
    Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M et al (2006) Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem Biophys Res Commun 343:303–310CrossRefPubMedGoogle Scholar
  17. 17.
    Peterson SJ, Frishman WH, Abraham NG (2009) Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 17:99–111CrossRefPubMedGoogle Scholar
  18. 18.
    Bauer M, Huse K, Settmacher U, Claus RA (2008) The heme oxygenase-carbon monoxide system: regulation and role in stress response and organ failure. Intensive Care Med 34:640–648CrossRefPubMedGoogle Scholar
  19. 19.
    Pecinová A, Drahota Z, Nůsková H, Pecina P, Houštěk J (2011) Evaluation of basic mitochondrial functions using rat tissue homogenates. Mitochondrion 11:722–728CrossRefPubMedGoogle Scholar
  20. 20.
    Austin RC, Sood SK, Dorward AM, Singh G, Shaughnessy SG, Pamidi S, Outinen PA, Weitz JI (1998) Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. J Biol Chem. 273:30808–30817CrossRefPubMedGoogle Scholar
  21. 21.
    Zivkovic V, Jakovljevic V, Pechanova O, Srejovic I, Joksimovic J, Selakovic D et al (2013) Effects of dl-homocysteine thiolactone on cardiac contractility, coronary flow, and oxidative stress markers in the isolated rat heart: the role of different gasotransmitters. Biomed Res Int. 2013:318–471CrossRefGoogle Scholar
  22. 22.
    Stanic M, Zakrzewska J, Hadzibrahimovic M, Zizic M, Markovic Z, Vucinic Z et al (2013) Oxygen regulation of alternative respiration in fungus Phycomyces blakesleeanus: connection with phosphate metabolism. Res Microbiol 164:770–778CrossRefPubMedGoogle Scholar
  23. 23.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  24. 24.
    Jakubowski H (2008) The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 59(Suppl 9):155–167PubMedGoogle Scholar
  25. 25.
    Jakubowski H (2007) The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med 45:1704–1716CrossRefPubMedGoogle Scholar
  26. 26.
    Dopner S, Hildebrandt P, Rosell FI, Mauk AG, von Walter M, Buse G et al (1999) The structural and functional role of lysine residues in the binding domain of cytochrome c in the electron transfer to cytochrome c oxidase. Eur J Biochem 261:379–391CrossRefPubMedGoogle Scholar
  27. 27.
    Perla-Kajan J, Marczak L, Kajan L, Skowronek P, Twardowski T, Jakubowski H (2007) Modification by homocysteine thiolactone affects redox status of cytochrome C. Biochemistry 46:6225–6231CrossRefPubMedGoogle Scholar
  28. 28.
    Zivkovic V, Jakovljevic V, Djordjevic D, Vuletic M, Barudzic N, Djuric D (2012) The effects of homocysteine-related compounds on cardiac contractility, coronary flow, and oxidative stress markers in isolated rat heart. Mol Cell Biochem 370(1–2):59–67CrossRefPubMedGoogle Scholar
  29. 29.
    Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417:1–13CrossRefPubMedGoogle Scholar
  30. 30.
    Jacobsen DW (2000) Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol 20:1182–1184CrossRefPubMedGoogle Scholar
  31. 31.
    Winterbourn CC, Peskin AV, Parsons-Mair HN (2002) Thiol oxidase activity of copper, zinc superoxide dismutase. J Biol Chem 277:1906–1911CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Jovana Jakovljević Uzelac
    • 1
  • Marina Stanić
    • 2
  • Danijela Krstić
    • 3
  • Mirjana Čolović
    • 4
  • Dragan Djurić
    • 1
  1. 1.Faculty of Medicine, Institute of Medical Physiology “Richard Burian”University of BelgradeBelgradeSerbia
  2. 2.Department for Life Sciences, Institute for Multidisciplinary ResearchUniversity of BelgradeBelgradeSerbia
  3. 3.Faculty of Medicine, Institute of Medical ChemistryUniversity of BelgradeBelgradeSerbia
  4. 4.Department of Physical Chemistry, “Vinča” Institute of Nuclear SciencesUniversity of BelgradeBelgradeSerbia

Personalised recommendations